Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer

Nagy Z. Takácsi, Ferenc Oberna, Pál Koltai, E. Hitre, T. Major, J. Fodor, C. Polgár

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To report the long-term results of a prospective, nonrandomized clinical trial using high-dose-rate (HDR) brachytherapy (BT) for the management of base of the tongue (BOT) tumors. Methods and Materials: Between January 1992 and June 2011, 60 patients (mean age, 57 years; range, 36-78 years) with T1-T4 and N0-3 carcinoma of BOT were treated. Fifty-six patients (93%) had advanced (Stage III-IV) disease. HDR BT boost (mean dose, 17Gy; range, 12-30Gy) was delivered after 50-70Gy (mean 62Gy) locoregional external beam irradiation. Seventeen patients (28%) received radiochemotherapy (RCT) with cisplatin. Results: The 5-year actuarial rate of local tumor control, locoregional tumor control, overall survival (OS), and cancer-specific survival (CSS) was 57%, 50%, 47%, and 61%, respectively. OS was significantly better in patients (n= 17) receiving RCT (69% vs. 39%; p= 0.005). Delayed soft-tissue ulceration occurred in seven patients (12%). Only one patient (

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalBrachytherapy
Volume12
Issue number6
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Tongue Neoplasms
Brachytherapy
Chemoradiotherapy
Tongue
Survival
Neoplasms
Cisplatin
Carcinoma

Keywords

  • Base of tongue
  • Brachytherapy
  • HDR

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer. / Takácsi, Nagy Z.; Oberna, Ferenc; Koltai, Pál; Hitre, E.; Major, T.; Fodor, J.; Polgár, C.

In: Brachytherapy, Vol. 12, No. 6, 11.2013, p. 535-541.

Research output: Contribution to journalArticle

@article{d8f7d4046d734382a8049fabfbff5729,
title = "Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer",
abstract = "Purpose: To report the long-term results of a prospective, nonrandomized clinical trial using high-dose-rate (HDR) brachytherapy (BT) for the management of base of the tongue (BOT) tumors. Methods and Materials: Between January 1992 and June 2011, 60 patients (mean age, 57 years; range, 36-78 years) with T1-T4 and N0-3 carcinoma of BOT were treated. Fifty-six patients (93{\%}) had advanced (Stage III-IV) disease. HDR BT boost (mean dose, 17Gy; range, 12-30Gy) was delivered after 50-70Gy (mean 62Gy) locoregional external beam irradiation. Seventeen patients (28{\%}) received radiochemotherapy (RCT) with cisplatin. Results: The 5-year actuarial rate of local tumor control, locoregional tumor control, overall survival (OS), and cancer-specific survival (CSS) was 57{\%}, 50{\%}, 47{\%}, and 61{\%}, respectively. OS was significantly better in patients (n= 17) receiving RCT (69{\%} vs. 39{\%}; p= 0.005). Delayed soft-tissue ulceration occurred in seven patients (12{\%}). Only one patient (",
keywords = "Base of tongue, Brachytherapy, HDR",
author = "Tak{\'a}csi, {Nagy Z.} and Ferenc Oberna and P{\'a}l Koltai and E. Hitre and T. Major and J. Fodor and C. Polg{\'a}r",
year = "2013",
month = "11",
doi = "10.1016/j.brachy.2013.07.001",
language = "English",
volume = "12",
pages = "535--541",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Long-term outcomes with high-dose-rate brachytherapy for the management of base of tongue cancer

AU - Takácsi, Nagy Z.

AU - Oberna, Ferenc

AU - Koltai, Pál

AU - Hitre, E.

AU - Major, T.

AU - Fodor, J.

AU - Polgár, C.

PY - 2013/11

Y1 - 2013/11

N2 - Purpose: To report the long-term results of a prospective, nonrandomized clinical trial using high-dose-rate (HDR) brachytherapy (BT) for the management of base of the tongue (BOT) tumors. Methods and Materials: Between January 1992 and June 2011, 60 patients (mean age, 57 years; range, 36-78 years) with T1-T4 and N0-3 carcinoma of BOT were treated. Fifty-six patients (93%) had advanced (Stage III-IV) disease. HDR BT boost (mean dose, 17Gy; range, 12-30Gy) was delivered after 50-70Gy (mean 62Gy) locoregional external beam irradiation. Seventeen patients (28%) received radiochemotherapy (RCT) with cisplatin. Results: The 5-year actuarial rate of local tumor control, locoregional tumor control, overall survival (OS), and cancer-specific survival (CSS) was 57%, 50%, 47%, and 61%, respectively. OS was significantly better in patients (n= 17) receiving RCT (69% vs. 39%; p= 0.005). Delayed soft-tissue ulceration occurred in seven patients (12%). Only one patient (

AB - Purpose: To report the long-term results of a prospective, nonrandomized clinical trial using high-dose-rate (HDR) brachytherapy (BT) for the management of base of the tongue (BOT) tumors. Methods and Materials: Between January 1992 and June 2011, 60 patients (mean age, 57 years; range, 36-78 years) with T1-T4 and N0-3 carcinoma of BOT were treated. Fifty-six patients (93%) had advanced (Stage III-IV) disease. HDR BT boost (mean dose, 17Gy; range, 12-30Gy) was delivered after 50-70Gy (mean 62Gy) locoregional external beam irradiation. Seventeen patients (28%) received radiochemotherapy (RCT) with cisplatin. Results: The 5-year actuarial rate of local tumor control, locoregional tumor control, overall survival (OS), and cancer-specific survival (CSS) was 57%, 50%, 47%, and 61%, respectively. OS was significantly better in patients (n= 17) receiving RCT (69% vs. 39%; p= 0.005). Delayed soft-tissue ulceration occurred in seven patients (12%). Only one patient (

KW - Base of tongue

KW - Brachytherapy

KW - HDR

UR - http://www.scopus.com/inward/record.url?scp=84887607603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887607603&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2013.07.001

DO - 10.1016/j.brachy.2013.07.001

M3 - Article

VL - 12

SP - 535

EP - 541

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 6

ER -